[go: up one dir, main page]

FR25C1012I1 - Posologie d'un agoniste du récepteur s1p - Google Patents

Posologie d'un agoniste du récepteur s1p

Info

Publication number
FR25C1012I1
FR25C1012I1 FR25C1012C FR25C1012C FR25C1012I1 FR 25C1012 I1 FR25C1012 I1 FR 25C1012I1 FR 25C1012 C FR25C1012 C FR 25C1012C FR 25C1012 C FR25C1012 C FR 25C1012C FR 25C1012 I1 FR25C1012 I1 FR 25C1012I1
Authority
FR
France
Prior art keywords
dosage
receptor agonist
agonist
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR25C1012C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41667217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR25C1012(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of FR25C1012I1 publication Critical patent/FR25C1012I1/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR25C1012C 2008-12-22 2025-04-08 Posologie d'un agoniste du récepteur s1p Active FR25C1012I1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US13967208P 2008-12-22 2008-12-22
US21853009P 2009-06-19 2009-06-19
US24671509P 2009-09-29 2009-09-29
EP16182876.9A EP3120844A1 (fr) 2008-12-22 2009-12-21 Régime posologique pour un agoniste du récepteur s1p
EP15158251.7A EP2907511A1 (fr) 2008-12-22 2009-12-21 Régime posologique pour un agoniste du récepteur s1p
EP09797234.3A EP2379067B1 (fr) 2008-12-22 2009-12-21 Regime posologique pour fingolimod pour le traitement de la sclerose en plaques
EP18201062.9A EP3453387B1 (fr) 2008-12-22 2009-12-21 Posologie d'un agoniste du récepteur s1p
PCT/US2009/068888 WO2010075239A1 (fr) 2008-12-22 2009-12-21 Régime posologique pour un agoniste du récepteur s1p
EP20160225.7A EP3677260A1 (fr) 2008-12-22 2009-12-21 Posologie d'un agoniste du récepteur s1p

Publications (1)

Publication Number Publication Date
FR25C1012I1 true FR25C1012I1 (fr) 2025-06-13

Family

ID=41667217

Family Applications (2)

Application Number Title Priority Date Filing Date
FR20C1060C Active FR20C1060I1 (fr) 2008-12-22 2020-11-19 Régime posologique pour un agoniste du récepteur s1p
FR25C1012C Active FR25C1012I1 (fr) 2008-12-22 2025-04-08 Posologie d'un agoniste du récepteur s1p

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR20C1060C Active FR20C1060I1 (fr) 2008-12-22 2020-11-19 Régime posologique pour un agoniste du récepteur s1p

Country Status (43)

Country Link
US (12) US20100160259A1 (fr)
EP (7) EP3120844A1 (fr)
JP (7) JP2012513401A (fr)
KR (1) KR101347919B1 (fr)
CN (1) CN102264359A (fr)
AR (1) AR074826A1 (fr)
AU (1) AU2009330176C9 (fr)
BR (1) BRPI0923500A2 (fr)
CA (1) CA2747802C (fr)
CL (2) CL2011001529A1 (fr)
CO (1) CO6390117A2 (fr)
CR (1) CR20110274A (fr)
CU (1) CU20110136A7 (fr)
CY (4) CY1116990T1 (fr)
DK (4) DK3409274T3 (fr)
EA (1) EA201100978A1 (fr)
EC (1) ECSP11011222A (fr)
ES (4) ES3017254T3 (fr)
FI (2) FI4098256T3 (fr)
FR (2) FR20C1060I1 (fr)
HN (1) HN2011001759A (fr)
HR (4) HRP20151190T1 (fr)
HU (6) HUE048717T4 (fr)
IL (3) IL213170A0 (fr)
LT (5) LT3453387T (fr)
LU (1) LUC00183I2 (fr)
MA (1) MA32981B1 (fr)
ME (2) ME03594B (fr)
MX (3) MX2011006623A (fr)
NO (1) NO2020038I1 (fr)
NZ (1) NZ593065A (fr)
PE (1) PE20120337A1 (fr)
PL (4) PL3453387T3 (fr)
PT (4) PT3453387T (fr)
RS (3) RS66784B9 (fr)
SG (1) SG171404A1 (fr)
SI (4) SI3409274T1 (fr)
SM (2) SMT202000441T1 (fr)
TN (1) TN2011000272A1 (fr)
TW (1) TW201028143A (fr)
UY (1) UY32352A (fr)
WO (1) WO2010075239A1 (fr)
ZA (2) ZA201103863B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101718639B1 (ko) 2008-03-17 2017-03-21 액테리온 파마슈티칼 리미티드 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생
HRP20151190T1 (hr) 2008-12-22 2016-01-01 Novartis Ag Režim doziranja za fingolimod u lijeäśenju multiple skleroze
US20120264719A1 (en) 2009-09-29 2012-10-18 Craig Boulton Dosage regimen of an s1p receptor modulator
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
SG10201500639TA (en) 2010-01-27 2015-03-30 Arena Pharm Inc Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
EP2566473B1 (fr) * 2010-05-06 2016-01-06 Novartis AG Posologie de dérivés de sulfure de diaryle
EP2455080A1 (fr) * 2010-11-23 2012-05-23 Almirall, S.A. Agonistes de récepteur S1P1 à utiliser dans le traitement de la sclérose en plaques
FR2968556B1 (fr) 2010-12-13 2013-12-27 Centre Nat Rech Scient Inhibiteurs des infections a vih et leurs utilisations
BR112013017302B1 (pt) 2011-01-07 2021-12-07 Novartis Ag Composição farmacêutica em fase sólida
JP6133790B2 (ja) 2011-02-18 2017-05-24 ザ スクリプス リサーチ インスティテュート ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
US9592268B2 (en) 2011-05-23 2017-03-14 Cornell University Endothelium protective materials and methods of use
TW201320994A (zh) 2011-10-11 2013-06-01 Novartis Ag 投藥療程
SI2885266T1 (sl) 2012-08-17 2020-10-30 Actelion Pharmaceuticals Ltd Postopek za pripravo (2Z,5Z)-5-(3-kloro-4-((R)-2,3-dihidroksipropoksi) benziliden)-2-(propilimino)-3-(O-tolil)tiazolidin-4-on in v omenjenem postopku uporabljena vmesna spojina
EP2964249A1 (fr) * 2013-03-06 2016-01-13 Acorda Therapeutics, Inc. Dosage thérapeutique d'une neuréguline ou d'un fragment associé pour le traitement ou la prophylaxie de l'insuffisance cardiaque
US10675254B2 (en) 2013-10-11 2020-06-09 Teikoku Seiyaku Co., Ltd. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
WO2015053878A1 (fr) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Formulations topiques agonistes du récepteur de la sphingosine-1-phosphate et procédés d'utilisation de celles-ci
US20170027907A1 (en) * 2014-04-10 2017-02-02 Eric Legangneux Sip modulator immediate release dosage regimen
WO2016091996A1 (fr) 2014-12-11 2016-06-16 Actelion Pharmaceuticals Ltd Régime posologique pour un agoniste de récepteur s1p1 sélectif
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
ES2995737T3 (en) * 2015-01-06 2025-02-11 Arena Pharm Inc Compound for use in treating conditions related to the s1p1 receptor
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
MA42807A (fr) 2015-06-22 2018-07-25 Arena Pharm Inc Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
WO2018151873A1 (fr) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Composés et méthodes de traitement de l'angiocholite biliaire primitive
CA3053416A1 (fr) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Composes et methodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales
EP3801459B1 (fr) 2018-06-06 2024-08-07 Arena Pharmaceuticals, Inc. Méthodes de traitement de troubles associés au récepteur s1p1
PH12022551043A1 (en) 2019-10-31 2023-05-03 Idorsia Pharmaceuticals Ltd Combination of a cxcr7 antagonist with an s1p1 receptor modulator
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator
WO2021158848A1 (fr) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Régime posologique d'un agoniste du récepteur s1p
JP2023515612A (ja) * 2020-02-28 2023-04-13 アカール・ファーマ・プロプライエタリー・リミテッド Ｓ１ｐ受容体調節物質
CN113332435B (zh) * 2021-06-18 2022-10-18 广州中医药大学(广州中医药研究院) 鞘氨醇-1-磷酸4受体激动剂及其与真武汤联合在制备治疗慢性肾小球肾炎药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122011100012I1 (de) 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-Amino-1, 3-propandiolverbindung und immunosuppressium.
CA2421893A1 (fr) 2000-08-31 2002-03-07 Merck And Co., Inc. Derives de phosphates utilises en tant qu'agents immuno-regulateurs
ES2316758T3 (es) 2002-05-16 2009-04-16 Novartis Ag Uso de aglutinantes del receptor edg en el cancer.
EP1663188B1 (fr) * 2003-09-12 2016-08-10 Newron Sweden AB Traitement de maladies ou de lesions du systeme nerveux avec le fty720
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
KR20130041385A (ko) * 2004-11-29 2013-04-24 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
EP1688141A1 (fr) * 2005-01-31 2006-08-09 elbion AG Utilisation de flupirtine pour le traitement de la vessie hyperactive et des maladies associées et pour le traitement du syndrome du colon irritable
CN101541227B (zh) * 2005-02-10 2013-06-05 G.I.视频有限公司 用于带导向元件的胃肠工具的前进技术
AR068986A1 (es) * 2007-10-12 2009-12-23 Novartis Ag Composiciones que comprenden moduladores del receptor de fosfato de esfingosina-1 (s1p)
KR101718639B1 (ko) 2008-03-17 2017-03-21 액테리온 파마슈티칼 리미티드 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생
SG10201406263SA (en) * 2008-06-20 2015-02-27 Novartis Ag Paediatric compositions for treating multiple sclerosis
HRP20151190T1 (hr) 2008-12-22 2016-01-01 Novartis Ag Režim doziranja za fingolimod u lijeäśenju multiple skleroze
JP5657565B2 (ja) 2008-12-22 2015-01-21 ノバルティス アーゲー Ｓ１ｐ受容体アゴニストの投与レジメン

Also Published As

Publication number Publication date
ES2552823T3 (es) 2015-12-02
RS60666B1 (sr) 2020-09-30
HUE052048T2 (hu) 2021-04-28
MX385959B (es) 2025-03-18
CL2013001558A1 (es) 2013-10-25
JP2016135752A (ja) 2016-07-28
FIC20253002I1 (fi) 2025-05-23
LTPA2025520I1 (fr) 2025-06-25
CR20110274A (es) 2011-07-19
CA2747802C (fr) 2021-02-09
HN2011001759A (es) 2013-11-26
EP3409274B1 (fr) 2019-11-20
JP2014144970A (ja) 2014-08-14
PE20120337A1 (es) 2012-04-24
ME03594B (fr) 2020-07-20
SI4098256T1 (sl) 2025-06-30
CN102264359A (zh) 2011-11-30
ZA201103863B (en) 2012-10-31
CY2020036I1 (el) 2021-03-12
AU2009330176A1 (en) 2011-07-07
EP3409274A1 (fr) 2018-12-05
SG171404A1 (en) 2011-07-28
PL2379067T3 (pl) 2016-02-29
JP2019167360A (ja) 2019-10-03
EP3120844A1 (fr) 2017-01-25
PL3453387T3 (pl) 2020-11-02
ME03802B (fr) 2021-04-20
US20170189353A1 (en) 2017-07-06
AU2009330176C9 (en) 2017-01-05
EP3677260A1 (fr) 2020-07-08
RS59857B1 (sr) 2020-02-28
HRP20151190T1 (hr) 2016-01-01
LT3453387T (lt) 2020-08-25
EP2907511A1 (fr) 2015-08-19
JP2022103194A (ja) 2022-07-07
US20100160259A1 (en) 2010-06-24
US20160081949A1 (en) 2016-03-24
CL2011001529A1 (es) 2012-02-24
SMT202000054T1 (it) 2020-03-13
EP4098256A1 (fr) 2022-12-07
MA32981B1 (fr) 2012-01-02
JP2012513401A (ja) 2012-06-14
PT3409274T (pt) 2019-12-17
EP3453387B1 (fr) 2020-06-03
JP7329965B2 (ja) 2023-08-21
TW201028143A (en) 2010-08-01
PL3409274T3 (pl) 2020-06-01
HUS2000046I1 (hu) 2020-12-28
KR101347919B1 (ko) 2014-01-07
HRP20192175T1 (hr) 2020-03-20
JP2024129030A (ja) 2024-09-26
LT4098256T (lt) 2025-06-10
US20140066657A1 (en) 2014-03-06
SI2379067T1 (sl) 2016-01-29
EP4098256B1 (fr) 2025-02-26
HUE071189T2 (hu) 2025-08-28
IL274756A (en) 2020-07-30
NO2020038I1 (no) 2020-11-18
AU2009330176C1 (en) 2016-12-08
US20110257133A1 (en) 2011-10-20
KR20110096175A (ko) 2011-08-29
LUC00183I2 (fr) 2024-07-01
ZA201205942B (en) 2013-03-27
ES3017254T3 (en) 2025-05-12
SI3453387T1 (sl) 2020-10-30
US20190091180A1 (en) 2019-03-28
PL4098256T3 (pl) 2025-06-09
US20140148415A1 (en) 2014-05-29
AU2009330176B2 (en) 2014-03-06
DK3453387T3 (da) 2020-08-10
DK4098256T3 (da) 2025-04-22
FR20C1060I1 (fr) 2020-12-25
EP2379067B1 (fr) 2015-09-02
CA2747802A1 (fr) 2010-07-01
SMT202000441T1 (it) 2020-09-10
EP2379067A1 (fr) 2011-10-26
DK3409274T3 (da) 2019-12-16
IL278914A (en) 2021-01-31
ES2810823T3 (es) 2021-03-09
PT3453387T (pt) 2020-08-11
CY2020036I2 (el) 2021-06-25
TN2011000272A1 (en) 2012-12-17
FI4098256T3 (fi) 2025-03-31
MX2021010759A (es) 2022-07-19
PT2379067E (pt) 2015-12-23
WO2010075239A1 (fr) 2010-07-01
HRP20250568T1 (hr) 2025-07-04
EP4098256B9 (fr) 2025-06-18
HUE026869T2 (en) 2016-08-29
ECSP11011222A (es) 2011-08-31
PT4098256T (pt) 2025-04-10
CY1123255T1 (el) 2021-10-29
US20250262171A1 (en) 2025-08-21
CU20110136A7 (es) 2012-01-31
HUE048717T2 (hu) 2020-08-28
SI3409274T1 (sl) 2020-03-31
ES2760607T3 (es) 2020-05-14
DK2379067T3 (en) 2015-12-07
MX2011006623A (es) 2011-07-12
RS66784B9 (sr) 2025-08-29
CY1122812T1 (el) 2021-05-05
HRP20201167T1 (hr) 2020-12-11
LT3409274T (lt) 2020-02-10
US20220142949A1 (en) 2022-05-12
JP2017141238A (ja) 2017-08-17
CO6390117A2 (es) 2012-02-29
IL213170A0 (en) 2011-07-31
DK4098256T5 (da) 2025-07-21
HUE048717T4 (hu) 2022-02-28
US20180289638A1 (en) 2018-10-11
US20200330407A1 (en) 2020-10-22
BRPI0923500A2 (pt) 2018-05-29
US20160263061A1 (en) 2016-09-15
CY1116990T1 (el) 2017-04-05
EA201100978A1 (ru) 2012-01-30
LTPA2020005I1 (lt) 2020-12-10
UY32352A (es) 2010-07-30
NZ593065A (en) 2012-11-30
EP3453387A1 (fr) 2019-03-13
AR074826A1 (es) 2011-02-16
HUS2500026I1 (hu) 2025-07-28
RS66784B1 (sr) 2025-06-30

Similar Documents

Publication Publication Date Title
FR25C1012I1 (fr) Posologie d'un agoniste du récepteur s1p
FR20C1022I2 (fr) Posologie d'un agoniste du recepteur s1p
MA29034B1 (fr) Posologie d'un agoniste du recepteur s1p
EP2150115A4 (fr) Antagonistes du récepteur de la cyclopropylpyrrolidine orexine
KR101522157B9 (ko) Ｃｏｍｔ 억제제의 투약 방법
EP2120575A4 (fr) Composés d'agonistes et d'antagonistes des récepteurs de sphingosine-1-phosphate
HRP20170246T1 (hr) Režim doziranja za selektivni agonist s1p1-receptora
DK2252581T3 (da) Kappa-selektiv opioidreceptorantagonist
EP2435061A4 (fr) Composés agonistes du récepteur glp-1 pour amélioration du sommeil
EP2427430A4 (fr) Composés antagonistes des récepteurs 5-oxo-ete
ATE485270T1 (de) 2-phenylindole als antagonisten des prostaglandin-d2-rezeptors
EP2773352A4 (fr) 4-arylpipérazine 1-substitué à titre d'antagoniste du récepteur opioïde kappa
EP2249833A4 (fr) Promédicaments d'antagoniste des récepteurs du cgrp
DK2131818T3 (da) Ny doseringsform
EP2271346A4 (fr) Antagonistes des récepteurs cgrp monocycliques
EP2365748A4 (fr) Antagonistes imidazoisoindoles des récepteurs du neuropeptide s
EP2341919A4 (fr) Antagonistes des récepteurs du cgrp
EP2089019A4 (fr) Polymorphes d'un antagoniste des récepteurs de tachykinine hydro-iso-indolique
EP2331101A4 (fr) Antagonistes du récepteur cgrp d'amide monocyclique
ZA200903873B (en) Sphingosine-1-phosphate receptor agonist and antagonist compounds
BRPI1014548A2 (pt) Métodos de administração de compostos agonistas de trombopoetina
EP2291076A4 (fr) Antagonistes du récepteur de l'angiotensine ll
TH0901005765A (th) ข้อกำหนดขนาดใช้สำหรับตัวทำการของตัวรับ S1P (S1P Receptor Agonist)
UA17747S (uk) Пристрій для обстеження трубопроводів «гном-100 д»
UA17286S (uk) Конструкція для розміщення інформації («хаус-лайт» квадро)